Platelets and Extracorporeal Membrane Oxygenation Veno-venous

In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.

NCT Number	NCT07580469
Lead Sponsor	University Hospital, Toulouse
Conditions	Extracorporeal Membrane Oxygenation Complication, Hemorrhage, Blood Platelet Disorder, Thrombosis
Enrollment	40 participants
Start Date	2026-09
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-29